 
|
  |
  |
  |
 
|
  |
  |
| Overview |
|
At KAI, we are leveraging our core expertise in selective protein kinase C modulation to advance product candidates quickly from preclinical research into clinical development. Our current clinical programs are focused in the areas of acute cardiovascular disease, pain, and secondary hyperparathyroidism (SHPT).
|
|||||||||||||||||||||||||||||||||||||||||||||||||
